Wkw Seto

Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection

Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non‐invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core‐related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB.

748 OUTCOME OF 4-YEAR TREATMENT OF ENTECAVIR FOR TREATMENT-NAIVE CHRONIC HEPATITIS B

This journal supplement is Abstract Book of the International Liver Congress 2011 by EASL (46th Annual Meeting)

Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B

Factors influencing changes in liver stiffness measurements during long‐term nucleoside analogue therapy for chronic hepatitis B (CHB) have not been thoroughly investigated.

Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study

The temporal relationship between nucleoside analogue therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level.

Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection

We studied the intrahepatic hepatitis B virus (HBV) replicative status in 40 people with occult hepatitis B infection (OBI) and 40 patients with chronic hepatitis B (CHB). Intrahepatic HBV DNA, covalently closed circular DNA (cccDNA), and pre-genomic RNA (pgRNA) were quantified. Patients with OBI had median necroinflammation and fibrosis scores of 1 and 0, respectively. Intrahepatic total HBV DNA, cccDNA and pgRNA were detectable in 30 (77%), one (3%) and five (13%) of the participants with OBI, respectively. People with OBI had lower median intrahepatic total HBV DNA than the patients with CHB (p < 0.0001). They had nearly normal liver histology and low intrahepatic HBV replication.

A Territory-Wide Study on the Seroprevalence of Hepatitis B Virus in the General Population after Universal Hepatitis B Immunization ERA in Hong Kong, China

Poster Presentations: Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy): no. THU-162

Hepatitis B surface antigen levels predict minimal histologic changes in hepatitis B e antigen positive chronic hepatitis B

The 22nd Conference of the Asian Pacific Association for the Study of the Liver APASL 2012—Taipei, Taiwan—16–19 February

Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B

Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis B (CHB).

Hepatitis B virus serological and virological activities in blood donors with occult hepatitis B

23rd Annual Conference of APASL March 12–15, 2014, Brisbane, Australia Asian Pacific Association for the Study of the Liver 2014 Topic: 1 Acute Liver Failure

Elevation of ALT fails to predict significant histologic abnormalities in chronic hepatitis B patients

The 21st Conference of the Asian Pacific Association for the Study of the Liver